Mobile app for alcohol cessation in liver disease patients
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease (IMPACT-ALD): Aim 1
This study is testing whether a smartphone app can help people with alcohol-related liver disease stop drinking more effectively than just regular care alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 298 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 3 sites (Lansing, Michigan and 2 other locations) |
| Trial ID | NCT06305624 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of the CHESS Health Connections smartphone application in helping patients with alcohol-associated liver disease (ALD) achieve alcohol cessation. Conducted at two major medical centers in Michigan and Wisconsin, the trial will enroll 298 participants who will be monitored for up to 6 months. The study compares the outcomes of patients using the app alongside usual care to those receiving only usual care, aiming to improve abstinence rates and liver function. Additionally, qualitative interviews will assess the implementation of the app within clinical settings.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with any stage of alcohol-associated liver disease who have consumed alcohol in the last 6 months and are receiving care at the participating medical centers.
Not a fit: Patients who are actively listed for liver transplant, in hospice care, or have severe cognitive impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance alcohol cessation rates and improve liver health in patients with alcohol-associated liver disease.
How similar studies have performed: Previous studies have shown promise in using mobile health applications for alcohol cessation, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of ALD (any stage) * Alcoholic liver disease (ALD) encompasses a spectrum of hepatic injuries caused by long-term alcohol abuse. For this study, participants will have a diagnosis of ALD or evidence of the combination of liver disease and alcohol misuse in electronic health record. * Alcohol use within the last 6 months * Receiving care at UW or Henry Ford Health + MSU * Either the general hepatology clinic or the multidisciplinary ALD clinic * Able to read and write proficiently in English * Willing and able to use a smartphone app Exclusion Criteria: * Actively listed for liver transplant or history of liver transplant before being enrolled in the study. Participants added to a liver transplant list after being enrolled in the study will be allowed to continue their participation * In hospice care * Has severe cognitive impairment (as described in electronic health record including dementia, delirium, and/or unable to maintain cognitive alertness during screening--as determined by study staff.)
Where this trial is running
Lansing, Michigan and 2 other locations
- Henry Ford + Michigan State University Health Center — Lansing, Michigan, United States (Recruiting)
- UW General Hepatology Clinic — Madison, Wisconsin, United States (Recruiting)
- UW Multidisciplinary ALD Clinic — Madison, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Andrew Quanbeck, PhD — University of Wisconsin, Madison
- Study coordinator: Jared P McDonald, MBA
- Email: jared.mcdonald@fammed.wisc.edu
- Phone: 608-263-4022
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.